Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.

Michael J SatlinParag GoyalReed MaglebyGrace A MaldarelliKhanh PhamMaiko KondoEdward J SchenckHanna RennertLars F WestbladeJustin J ChoiMonika M SaffordRoy M Gulick

Published in: PloS one (2020)

HCQ appears to be reasonably safe and tolerable in most hospitalized patients with COVID-19. However, nearly one-half of patients did not improve with this treatment, highlighting the need to evaluate HCQ and alternate therapies in randomized trials.

Keyphrases

coronavirus disease
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
open label
randomized controlled trial
patient reported
double blind
smoking cessation